Clinic Roundup

Halozyme Therapeutics Inc., of San Diego, said results in a Type I diabetes study of patients who receive their insulin treatment via pump demonstrated that Aspart-PH20, a formulation of the company's rHuPH20 (recombinant human hyaluronidase) with the active ingredient in NovoLog (aspart, Novo Nordisk A/S), accelerated insulin absorption and shortened its duration of action. Data were presented at the American Association of Clinical Endocrinologists meeting in San Diego.